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1. Introduction
Genomic DNA is susceptible to a variety of mutagenic processes. The maintenance of the
stability of genetic material, which is an important and essential feature of every living or‐
ganism, depends on an accurate DNA replication [1]. Organisms across all kingdoms have
developed diverse and highly efficient repair mechanisms to safeguard the genome from
deleterious consequences of various kinds of stresses that might tend to destabilize the in‐
tegrity of the genome. DNA is constantly being damaged. A low fidelity of DNA synthesis
in various compartments of the cells by main replicative DNA polymerases leads to genom‐
ic instability (mutator phenotype) [2]. The errors produced during DNA synthesis could re‐
sult from three fidelity determining processes: a)nucleotide misinsertion into the nascent
DNA, b)lack of exonucleolytic proofreading activity, i.e the mechanism to identify and ex‐
cise incorrect nucleotide incorporated during DNA synthesis, and c)extension of mismatch‐
ed 3’-termini of DNA [3]. Failure to repair DNA can lead to mutations, genomic instability,
chromosomal abnormalities, progression of cancer and premature aging.
Mutator phenotypes (with the potential for cancer progression) have been reported for cells
that lack a proofreading 3’→5’ exonuclease activity associated with the DNA polymerase [4].
Certain organisms with a deficiency of exonucleolytic proofreading, have an increased sus‐
ceptibility to cancer, especially under conditions of stress. Since cancer cells typically have
many mutations compared to a non-cancer cell, it was proposed that one of the earliest
changes in the development of a cancer cell is a mutation that increases the spontaneous
mutation rate [5]. Inactivation of 3′→ 5′ exonuclease activity in the mouse DNA pol δ in nu‐
cleus appears to produce replication errors that can drive evolution of a cancer. Mitochon‐
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drial DNA (mtDNA) alterations have been associated with various human diseases with
impaired mitochondrial function [6]. Mitochondrial DNA polymerase γ (pol γ) is responsi‐
ble for replication of mtDNA and is implicated in all repair processes [7]. Mitochondrial
DNA is prone to mutations, since it is localized near the inner mitochondrial membrane in
which reactive oxygene species are generated. Additionally, mtDNA lacks histone protec‐
tion and the highly efficient DNA repair mechanisms [8]. The mutation rate of mtDNA is
estimated to be about 20-100-fold higher than that of nuclear DNA [9]. The mutagenic mech‐
anisms were shown to be replication errors caused by misinsertion (as a result of a dNTP
excess), or decreased proofreading efficiency [10,11]. The biological importance of the 3’→5’
exonuclease activity of pol γ to mtDNA integrity is illustrated by the fact that mice encoding
an exonuclease-deficient form of pol γ have strongly elevated rates of base substitutions in
mtDNA and undergo accelerated aging [12].
Virulence, pathogenesis and the ability to develop effective antiretroviral drugs and vac‐
cines are largely dependent on genetic diversity in viruses [13]. Retroviruses are RNA virus‐
es that replicate through a DNA intermediate in a process catalyzed by the viral reverse
transcriptase (RT) in cytoplasm [14]. Human immunodeficiency virus type 1 (HIV-1), the
etiological agent of AIDS, exhibits exceptionally high mutation frequencies [15]. The accept‐
ed explanations for the inaccuracy of HIV-1 RT are the relatively low fidelity of the enzyme
during DNA synthesis and the deficiency of intrinsic 3′→5′ exonuclease activity [16-18]. A
strong mutator phenotype is also observed for herpes viral DNA polymerase mutants with
reduced intrinsic 3′→5′ exonuclease activity [19].
Thus, in various compartments of the cell increased DNA replication accuracy provided by
DNA polymerase proofreading activity is an essential activity for the maintenance of ge‐
nomic integrity for many organisms.
2. Exonucleases in protecting genome stability
The effect of misinsertion of a wrong nucleotide on the polymerase reaction can be either
inhibitory, leading to nascent chain termination and primer dissociation or non-inhibitory,
leading to mispair extension (resulting in the fixation of either transition or transversion mu‐
tations) (Fig 1). Exonucleolytic proofreading of polymerization errors is one of the major de‐
terminants of genome stability [20]. The physiological role for the exonucleolytic
proofreading has been proposed to be to increase the fidelity of DNA synthesis by excising
incorrectly polymerized nucleotides. Following the incorporation of a non-complementary
nucleotide at the 3′ end of the primer, exonucleolytic correction can occur by intrinsic exo‐
nuclease through intramolecular shuttling of the DNA substrate from the polymerase to the
3′→5′ exonucleolysis active site of the enzyme (e.g. pol γ, pol δ and pol ε) [1,4]. However,
there are DNA polymerases that do not possess an intrinsic proofreading function, e.g. cellu‐
lar DNA polymerases α and β, retroviral RTs [17,21,22]. Hence, during in vitro DNA synthe‐
sis by an inaccurate DNA polymerases, following the polymerase dissociation at a mispair,
misincorporated nucleotides could be removed by two kinds of an “external” proofreading
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carried out by the 3´→ 5´ exonuclease activity of other DNA polymerase [23] and/or by sepa‐
rate protein serving as a proofreading exonuclease [24,25]. The lack of intrinsic proofread‐
ing, combined with delayed chain elongation of mispaired 3'-ends could provide the
opportunity for a separate exonuclease to bind to the nascent DNA ends and excise the mis‐
paired nucleotides. Enzymes that contain 3’–5’ exonuclease activities are involved in main‐
taining genome stability. Proofreading in trans is a very efficient process, which has a
potential to allow exonuclease-proficient enzyme/protein to proofread for 3′→ 5′ exonu‐
clease-deficient DNA polymerases. Proteins with intrinsic proofreading activity may be im‐
portant for both, 3′→5′ exonuclease-deficient and exonuclease-proficient DNA polymerases.
The p53 protein is a member of external proteins that by intrinsic 3′→5′ exonuclease activity
may serve as proofreader and could be actively involved in DNA repair thereby significant‐
ly expanding the role of p53 as a guardian of the genome [26].
Figure 1. The outcomes of the misincorporation. DNA polymerases following a misincorporation of the wrong nucleo‐
tide, can either continue chain elongation beyond the mismatch or remove the mispaired terminus (if a proofreading
exonuclease is associated with DNA replication machinery) or block the DNA synthesis by dissociating from the tem‐
plate-primer.
3. p53 and DNA repair
The tumor suppressor protein p53 represents a central factor for the maintenance of genome
stability and for the suppression of cancer [27,28]. Under normal conditions within the cell




p53 is present at low levels, but after exposure to various stress signals, the protein is stabi‐
lized and functionally activated by a series of post-translational modifications, resulting in
p53 accumulation at nuclear and extranuclear sites [29,30]. The cellular level of p53 and the
nature of DNA damage can dictate the response of the cell. As p53 is a pleiotropic regulator,
it affects many processes. The biological outcomes of p53 functions as a sequence-specific
transcription factor include cell cycle arrest, apoptosis or DNA repair [31]. Apparently, cell
cycle arrest mediated by p53 in response to DNA damage allows time for the cells to repair
DNA. If the cells are unable to repair DNA damage, apoptosis is triggered by a p53-depend‐
ent pathway to eliminate the cells that contained damaged DNA. These processes together
ensure the integrity of the genome. p53 can affect DNA repair processes through its ability
to transactivate genes involved in these processes [28]. Mutations in p53 are the most fre‐
quent molecular alterations detected in human cancers. The loss of the functional p53 may
be responsible for genetic instability and the development of cancer [32].
Appropriate subcellular localization is critical for regulating function of p53. p53 is active‐
ly transported between the nucleus and cytoplasm. Furthermore, p53 translocates to mito‐
chondria.  The  sub-cellular  localization  of  p53  and the  interaction  with  other  cellular  or
viral proteins plays a central role in the regulation of its various biological activities [26].
p53 may modulate DNA repair through processes, which are independent of its transacti‐
vation function. p53 can directly interact with DNA repair related cellular factors includ‐
ing DNA polymerase β, AP endonuclease, Rad 51, and mammalian homologs of the RecQ
helicase family and Wrn proteins [33-36].  In addition, full  range of various intrinsic bio‐
chemical features of the p53 protein support its possible roles in DNA repair. After DNA
damage: (a) p53 is able to recognize and bind sites of DNA damage, such as single-strand‐
ed  (ss)  DNA  and  double-stranded  (ds)  DNA  ends  [37,38],  (b)  p53  catalyzes  DNA  and
RNA strand transfer and promotes the annealing of complementary DNA and RNA sin‐
gle-strands [39,40], (c) p53 binds insertion/deletion mismatches and bulges [41] and (d) it
can bind DNA in a non-sequence-specific manner [42]. Evidence suggesting a direct role
in DNA repair is  supported by observations that (1)  p53 increases transcription-coupled
nucleotide excision repair [43]; (2) p53, like classical mismatch repair factors, checks the fi‐
delity of  homologous recombination processes by specific  mismatch recognition [44];  (3)
p53  can  markedly  stimulate  base  excision  repair  [33,45];  (4)  p53  exhibits  3'→ 5'  exonu‐
clease activity and wild-type p53, but not mutant p53, enhanced the replication fidelity of
various  DNA polymerases  in  an in  vitro  replication assay,  strongly  supporting the  idea
that p53 can act as an exogenous proofreader for the replicases [46,47].
4. Characterization of p53 exonuclease activity
Highly purified p53 protein from different sources displays 3´→ 5´ exonuclease activity. p53
has no associated polymerase activity and catalyzes the excision of nucleotides from DNA
exclusively in the 3 ’to 5’direction [46]. This activity is dependent on the presence of Mg2+
and is intrinsic to the wtp53, since no exonuclease activity was detected with mutant p53
protein, e.g. 273His and 175His mutant p53s. Importantly, the exonuclease activity could be
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reconstituted from SDS gel-purified and urea-renatured p53 protein. While p53 exhibits op‐
timal transactivation as tetramer, it displays exonuclease activity as monomer [48]. Notably,
the oligomarization status of p53 may be important in determining whether protein may act
as transcription activator (tetramer) or as exonuclease (monomer).
p53 removes 3’-terminal nucleotides from various nucleic acids substrates: ssDNA, dsDNA
RNA/DNA template-primer, ssRNA and dsRNA [46-52]. A unique property of p53 is its
ability to excise nucleotides non-processively (on DNA <17 nucleotides) and processively
(on DNA >17 nucleotides) [48]. The purified wtp53 exhibits all hallmarks of a genuine proof‐
reading activity [49]. First, the protein shows a preference for degradation of ssDNA over
dsDNA substrate. Second, on partial duplex structures, the p53 exonuclease activity dis‐
plays a marked preference for excision of a mismatched versus a correctly paired 3´ termi‐
nus, which enables the protein to act as a proofreader. The intrinsic ability of p53
exonuclease to sequentially remove incorrect 3’ terminal nucleotides from DNA strands be‐
fore primer extension is important for subsequent elongation of primers during error correc‐
tion and renders the p53 protein essential in DNA replication, repair, and recombination.
Third, p53 acts coordinately with the DNA polymerase to enhance the fidelity of DNA syn‐
thesis by excision of mismatched nucleotides from the nascent DNA strand.
The proofreading capacity of p53 was observed during ongoing DNA synthesis in vitro; p53
exonuclease has a marked impact on the extent of mispair formation and on the extension
from specific mispaired termini by DNA polymerase [49]. Recombinant, as well as endoge‐
nous wtp53 can proofread for exonuclease-deficient cellular or viral DNA polymerases (e.g.
DNA polymerase α, DNA polymerase α-primase, HIV-1 RT) and exonuclease-proficient
DNA polymerase (e.g. pol γ), thus enhancing the accuracy of DNA synthesis by excising in‐
correctly polymerized nucleotides [53-57]. Apparently, the exonuclease activity of p53, by
removal of a mismatched nucleotide incorporated by a DNA polymerase, might provide a
biochemical basis for its direct involvement in the correction of replication errors. Notably,
the exonuclease activity of p53 must not be restricted to its non-induced state, but might also
be exerted by a subclass of p53 after DNA damage when the protein is able to display its full
range of possible biochemical activities [26]. Remarkably, p53 exonuclease excises nucleoti‐
des from RNA/DNA template-primers, a property which distinguishes it from the large ma‐
jority of the known exonucleases [50]. The fact that p53 is reactive with both DNA/DNA and
RNA/DNA suggests that it may functionally interact with substrates participating in the re‐
verse transcription process during the replication of retroviruses.
p53 is capable of excising 3'-terminal mispaired nucleotides in direct exonuclease assay inde‐
pendent of DNA polymerase; p53 is very active when first binding to a 3’-terminus [49,50]..
Some template-primers with terminal mispairs remain unextended by the polymerase. In‐
terestingly, unextended free template-primers (already dissociated from the enzyme follow‐
ing the misinsertion) may be further recognized by other DNA polymerase (e.g. HIV-1 RT)
molecules and undergo a rebinding process with a subsequent 3'-mismatch extension [58].
The fact that p53 excises terminal nucleotides independent of DNA polymerase [49,55] sug‐
gests that the dissociated unextended 3'-mismatch containing template-primer may be rec‐
ognized and utilized by p53 to remove terminal mispairs generating the correctly base-




paired 3'-termini necessary for continued DNA synthesis [49]. The recognition and binding
to 3´ mismatched ends is a prerequisite for the excision of mismatched or damaged nucleoti‐
des [42]. Endogenous p53 displays intrinsic 3'-terminal mispaired DNA binding activity.
Since p53 binds directly to various 3'-terminal purine:pyrimidine and purine:purine mis‐
pairs to an equal extent, it can be considered a general 3'-mismatched DNA binding protein.
Intrinsic 3'-terminal mismatched DNA binding capacity of p53 extends the spectrum of
DNA damage sites that p53 can recognize and bind. Through the binding p53 participates in
damage recognition, which serves as a signal for DNA repair. Thus, the role of p53 in proof‐
reading is two fold — to excise terminal mismatches, but also to prevent extension of mis‐
matched primer ends by DNA polymerase.
p53 intrinsic exonuclease activity, like sequence-specific DNA binding, was mapped to the
central conserved core domain of protein, which is the target for most of the missense muta‐
tions inactivating the tumor suppressor function of p53 [59]. It is noteworthy that bacterially
expressed, i.e., nonphosphorylated, p53 is virtually devoid of sequence-specific DNA bind‐
ing activity but exerts exonuclease activity [46], pointing to the possibility that the p53 exo‐
nuclease activity might be exerted by hypo- or even nonphosphorylated p53. Treatments
activating sequence-specific DNA binding of full-length p53 strongly inhibited its exonu‐
clease activity, indicating that p53 exonuclease and sequence-specific DNA binding are dis‐
tinct features of the p53 core domain, regulated in opposite manners. Apparently, p53 exerts
two complementary functions in maintaining the integrity of the genome. After damage dif‐
ferent functional subclasses of p53 will exist within the same cell, then the increase of p53
protein levels not only will activate the potential of p53 to transcribe p53 target genes, lead‐
ing to growth arrest, but will also increase the amount of p53 with a 3'→5' proofreading exo‐
nuclease activity. As its basal function in maintaining genetic stability, p53 participates
actively in repair processes of endogenous DNA damage and the prevention of mutational
events resulting from such damage, through activities not related to sequence-specific DNA
binding, specifically through its exonuclease activity [26]. Such p53 then could enhance the
accuracy of DNA repair synthesis performed by the error-prone DNA polymerases, e.g. pol
α and β. At another level of control, cellular stress activates the functions of p53 generally
associated with growth arrest and apoptosis.
Mutant H115N p53, showed markedly reduced exonuclease activity [60]. Surprisingly, puri‐
fied H115N p53 protein was found to be significantly more potent than wild-type p53 in
binding to DNA. Interestingly as well, non-specific DNA binding by the core domain of
H115N p53 is superior to that of wild-type p53. Unexpectedly, in contrast to wtp53, H115N
p53 was markedly impaired in causing apoptosis when cells were subjected to DNA dam‐
age facilitating apoptosis, further supporting the idea that the exonuclease activity and tran‐
scriptional activation functions of p53 can be separated. The impact of deficiency of
exonuclease activity in p53 is not known. This might be partly due to the observation that
tumor derived hot-spot mutants not only fail to function as transcriptional activators but al‐
so were reported to be deficient in exonuclease activity. p53 hot spot mutants were catego‐
rized into two classes; structural and functional mutants [61]. Since representative members
of both classes were defective in exonuclease activity, it is likely that both, structural integri‐
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ty of the protein and DNA binding activity are essential for each of these two biochemical
functions.
5. p53 exonuclease provides proofreading during DNA synthesis in
various compartments of cells
p53 activities are extended to normal and cancer cells and they efficiently contribute to ge‐
nome stability even in the absence of stresses. p53 is expressed constitutively in the cell and
is distributed in the nucleus, cytoplasm and mitochondria of unstressed and stressed cells.
5.1. p53 exonuclease activity in nucleus
The observation that p53 protein is co-located with the DNA replication machinery and may
preferentially remove mismatched nucleotides from DNA, suggests a link between p53 and
DNA replication fidelity [62]. The localization of p53 in nucleus is essential for its normal
function in growth inhibition or induction of apoptosis. The low accuracy of DNA polymer‐
ases and imbalance of intracellular dNTP pools are major factors in causing replication er‐
rors [3]. The proofreading for such replication errors by the 3´→ 5´ exonuclease activity
associated with the DNA replication machinery is extremely important in reduction the oc‐
currence of mutations. DNA polymerase α is lack of proofreading activity and is prone to
making replication errors [63]. p53 specifically interacts with DNA polymerase α and has
been shown to preferentially excise mismatched nucleotides from DNA and enhance the
DNA replication fidelity of DNA polymerase α in vitro [47]. The fact that p53 is able to en‐
hance the replication fidelity of pol α in vitro suggests that p53 may serve a proofreading
function during DNA replication in intact cells.
It is conceivable that cells lacking p53 exonuclease activity can demonstrate high mutation
frequency under stress conditions and the mutations should be reduced by introduction of
wild type p53 into the cells. Hydroxyurea (HU), an inhibitor of ribonucleotide reductase in‐
volved in the de novo synthesis of deoxynucleotides, was used to induce dNTP pool imbal‐
ance and to cause mutations in the cells due to misincorporation of unpaired
deoxynucleotides into DNA [54]. Cells with different states of p53 expression, either endo‐
genously or ectopically, were exposed to HU. The analysis of the rates of HU-induced muta‐
tions in H1299 (p53-null) and H460 (wtp53) cells revealed substantially increased mutation
rates in H1299 cells. Furthermore, the HU-induced mutation frequency was significantly re‐
duced by introduction of wild type p53 expression vector into the p53-null H1299 cells.
Thus, wild type p53 expression was associated with a reduction of mutations caused by rep‐
lication errors under the stress of dNTP pool imbalance [54]. p53, presumably, may play an
important role in reduction mutations caused by misincorporation of unpaired nucleotides.
This biological function of p53 in whole cells is consistent with its biochemical activity in
preferential removal of mismatched nucleotides from DNA by 3´→ 5´ exonuclease activity
and enhancing replication fidelity of DNA polymerase α in vitro. The reported association




of replication error phenotype with p53 mutations in mucosa-associated lymphoid tissue
lymphomas is consistent with the proofreading function of p53 [64].
It was shown that in the early steps of cellular transformation process high incidences of
mutations occur, which may be due to misinsertion and proofreading deficiency of DNA
polymerases [65]. The existence of complex pol-prim- p53 in vivo,  identified by immono‐
precipitation  experiments,  suggests  that  p53  might  cooperate  with  DNA  polymerase  to
maintain the genetic information in cells [53]. The functional interaction of DNA polymer‐
ase  and  exonuclease  activity  was  observed  with  p53/pol-prim  complex.  p53-containing
DNA pol-prim complex  excised  preferentially  a  3′-mispaired  primer  end  over  a  paired
one and replaced it  with  a  correctly  paired nucleotide.  In  contrast,  a  pol-prim complex
containing the hot  spot  mutant  p53R248H did not  display exonuclease  activity  and did
not  elongate  a  mispaired  3′-end,  indicating  that  the  p53  exonuclease  from the  p53/pol-
prim complex was mandatory for the subsequent elongation of the primer by DNA poly‐
merase. These findings support the view that p53 might fulfill a proofreading function for
pol-prim and suggest  that  the defect  in proofreading function of  p53 may contribute to
genetic instability associated with cancer development and progression.
Notably, the non-genotoxic stress may include a long-lasting, moderate accumulation of p53
in nucleus. In contrast, acute genotoxic stress may induce rapid and transient accumulation
of very high levels of p53 with preferential activation of target genes involved in apoptosis.
The in vivo experiments showed that while expression of low levels of p53 facilitate BER ac‐
tivity, higher levels reduced it and instead induced apoptosis, suggesting that p53 media‐
ting various activities are correlated with the levels of the p53 protein in the cells [66]. In this
regard, it is possible that the accumulation of p53 in nucleus allows the protein to function
in several ways: as a regulator of transcription, as a facilitator of BER and as an exonucleo‐
lytic proofreader. Moreover, there is a possibility that both transcription-independent path‐
ways act in synergy thereby amplifying the potency of involvement of p53 in DNA repair.
The presence of p53 was demonstrated in different nuclear compartments and suggested
that the p53 population not engaged in transcriptional regulation could exert functions other
than induction of growth arrest or apoptosis and directly participate in processes of repair
via its various biochemical activities [26].
5.2. p53 exonuclease activity in cytoplasm
p53 is retained in the cytoplasm during part of the normal cell cycle. Wild-type p53 occurs in
cytoplasm in a subset of human tumor cells such as breast cancers, colon cancers and neuro‐
blastoma [67-69]. Notably, cytoplasmic sequestration of p53 in tumor cells (that do not have
mutated p53), besides structural mutation and the functional inactivation of wtp53, was sug‐
gested to be an important mechanism in abolishing p53 function and in tumorigenesis
[67,70]. Shuttling between nucleus and cytoplasm not only regulates protein localization,
but also often impacts on protein function. Analyses of various cell lines (MCF-7 human
breast cancer cells – expressing high levels of wtp53 in nucleus, LCC2-subclone derived
from MCF-7 cells-expressing high levels of wtp53 in cytoplasm, MDA cells-expressing high
levels of mutant p53 or H1299-p53-null cells), demonstrated that the cytoplasmic extracts of
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non-stressed LCC2 cells, exert high level of 3´→ 5´ exonuclease activity [55,56]. Interestingly,
the 3´→ 5´ exonuclease in the cytoplasmic fraction from LCC2 cells displays identical bio‐
chemical functions characteristic for recombinant wtp53 [56]: 1)it removes 3′-terminal nu‐
cleotides from various nucleic acid substrates: ssDNA, dsDNA, and RNA/DNA template-
primers, 2)it hydrolyzes ssDNA in preference to dsDNA and RNA/DNA template-primers,
3)it shows a marked preference for excision of a mismatched vs correctly paired 3′ terminus
with RNA/DNA and DNA/DNA substrates, 4)it exerts the preferential excision of purine-
purine (transversion) mispairs over purine-pyrimidine (transition) mispairs, 5)it excises nu‐
cleotides from various nucleic acid substrates independently from DNA polymerase, 6) it
fulfils the requirements for proofreading function; acts coordinately with the exonuclease-
deficient viral (e.g. MLV RT, HIV-1 RT) and cellular DNA polymerases – (e.g. pol α and β)
(unpublished results) to enhance the fidelity of DNA synthesis by excision of mismatched
nucleotides from the nascent DNA strand [55,56]. It is noteworthy, that in non-stressed cells
p53 is constitutively expressed and exists in transcriptional inert state. Thus, the protein ex‐
erts exonuclease activity independently of p53 functions in transcription.
Interestingly, p53 protein in cytoplasmic extracts of MCF-7 cells displays a relatively high
level of 3´→ 5´ exonuclease activity in comparison to nuclear lysates of LCC2 cells [55]. The
biochemical difference between the p53 in nuclear and cytoplasmic compartments raises
questions whether nuclear p53 loses exonuclease function of cytoplasmic p53 or acquires an
additional functions (e.g. efficient sequence-specific DNA binding and transactivation). The
disparity in expression of p53 exonuclease activity may be attributable to the different post‐
transcriptional events: a)post-translational modifications (e.g. phosphorylation, acetylation)
may regulate the ability of p53 to serve as an exonuclease in the nucleus and in the cyto‐
plasm; b) The alteration of p53 protein conformation from mutant (in cytoplasm) to wild-
type (in nucleus) may be responsible for low level of exonuclease activity in nucleus [71]. c)
the interaction of p53 with other proteins and/or DNA polymerases may affect on expres‐
sion its various biochemical activities.
5.3. p53 exonuclease activity in mitochondria
Mitochondrial DNA mutations can arise from different sources, including errors made by
pol γ, the enzyme that replicates the mitochondrial genome. The mitochondrial pol γ be‐
longs to a family A DNA polymerase, and as observed for other family A DNA polymeras‐
es, this enzyme excises the terminal nucleotide at a much slower rate than observed for the
potent 3′→5′ exonuclease-proficient T4 DNA polymerase [72]. The mutagenic mechanisms
were shown to be replication errors caused by incorporation of wrong nucleotide (as a result
of a dNTP excess), or decreased proofreading efficiency. Furthermore, a potentially impor‐
tant source of replication infidelity is damage due to reactive oxygen species. Among several
known oxidized dNTPs, one that is particularly common and potentially highly mutagenic
is 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodG) [73]. Incorrect 8-oxo-dGTP-A base pair‐
ing can lead to A-T to C-G transversions if the incorporated 8-oxo-dGMP escapes proofread‐
ing and any subsequent repair. pol γ, was demonstrated to stably misincorporate 8-oxo-
dGTP opposite template adenine in a complete DNA synthesis reaction in vitro [74]. Low-




fidelity DNA synthesis in mitochondria was observed despite the presence of the intact
proofreading exonuclease, thus indicating that the 8-oxo-GMP-A mismatch was not effi‐
ciently proofread.
A certain fraction of p53 translocates to mitochondria. Mitochondrial localization of p53 was
observed in both stressed and non-stressed cells [75,76], where p53 was shown to physically
and functionally interact with both, the mtDNA and pol γ in response to mtDNA damage
induced by exogenous and endogenous insults [77]. p53 is localized in mitochondria to the
inside face of the inner membrane i.e, in matrix, the compartment in which mtDNA is locat‐
ed [57,77]. The functional cooperation of p53 and pol γ during DNA replication was studied
using the mitochondrial fraction of p53-null H1299 cells, as the source of pol γ [57]. p53 af‐
fected the accuracy of DNA replication by promoting excision of misincorporated nucleoti‐
des which increased in the presence of either added recombinant wild-type p53, or
endogenous p53 provided by the cytosolic extracts from H1299 cells over-expressing wild-
type p53, but not from cells expressing the exonuclease-deficient mutant p53–R175H. En‐
dogenous p53 in mitochondrial extracts of HCT116 (p53+/+) cells had increased exonuclease
activity compared with that from HCT116(p53-/-) cells and adding exogenous p53 comple‐
mented the HCT116(p53-/-) mitochondrial extract mediated mispair excision. Furthermore,
nucleotide misincorporation was reduced in the mitochondrial extracts of HCT116 (p53+/+)
cells compared with that of HCT116(p53-/-) cells. Irradiation-induced mitochondrial translo‐
cation of endogenous p53 in HCT116(p53+/+) cells correlated with the enhancement of error-
correction activities. This evidence strongly supports a direct role of p53 in mitochondria
providing exonuclease activity for DNA repair required for error-repair pathway [57].
Therefore, p53 not only serves as guardian of the nuclear genome but also of the mitochon‐
drial genome.
p53 interacts physically with mtDNA and pol γ in response to mtDNA damage induced by
endogenous insults including oxidative stress. The intrinsic exonuclease activity of pol γ
does not efficiently proofread 8-oxodG misinserted opposite adenine [78]. Once 8-oxo-
dGMP is incorporated opposite adenine by pol γ it is preferentially extended rather than ex‐
cised, which increases its mutagenic potential. Interestingly, human mitochondrial single-
stranded DNA binding protein (HmtSSB) was identified as a novel protein-binding partner
of p53 in mitochondria. HmtSSB enhances intrinsic 3'→5' exonuclease activity of p53, partic‐
ularly in hydrolysing 8-oxodG present at 3'-end of DNA, suggesting that p53 is directly in‐
volved in DNA repair within mitochondria during oxidative stress.
5.4. p53 exonucleolytic proofreading may affect the mutation spectra of DNA polymerase
The accuracy of DNA synthesis reflects complex interactions between the parameters of the
catalytic “triad” involved in DNA polymerization: DNA polymerase, the nature of the mis‐
pair and proofreading exonucleases (fidelity–enhancing accessory component) [1,22]. DNA
polymerase catalyzed both, misinsertion and mismatch extension reactions and the extent of
proofreading depend on the type of the mispair, and the influence of surrounding sequences
of the template. Various cellular and viral DNA polymerases share common pattern of mis‐
pair formation and extension: namely, purine-pyrimidine mispair (e.g. A:C mispair) is easily
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inserted and more efficiently extended than the purine-purine (e.g. A:A or A:G mispair) or
pyrimidine-pyrimidine mispair (e.g. C:C or C:T) [79,80]. Thus, the general trend of mispair
extension is A:C>A:A>A:G. Interestingly, p53 displays variation in excision of mismatched
base pairs; the protein exhibits preferential excision of purine-purine transversion mispairs
(e.g. A:A, A:G) over purine-pyrimidine transition mispairs (e.g. A:C, G:T) [49]. Apparently,
the variances in the extension and excision spectrum generated are different for these two
reactions. The mispair excision pattern (A:G>A:A>A:C) detected with p53 is an interesting
observation with respect to the contribution of proofreading to fidelity; it is compatible with
the mispair extension specificity obtained with this particular sequence studied.
The importance of the mispair extension efficiency as a fidelity parameter was illustrated by
the fact that an increased forward polymerization capacity for transition A:C mispair, as
compared to transversion A:G mispair, overcomes the ability of p53 exonuclease activity in
cytoplasm to excise nucleotide mispairs under the similar exonuclease to polymerase ratios
[56]. Indeed, the purine-pyrimidine mispair A:C (the most easily formed and extended) is
less efficiently excised and the purine-purine A:A and A:G mispairs (less efficiently formed
and extended), are rather efficiently excised. Therefore, it is conceivable that the structural
feature that make the mismatched terminus a poor substrate for elongation (polymerization)
is a good substrate for degradation (exonucleolysis) [81].
Remarkably, p53 exonuclease displays the same pattern of mispair excision specificity with
RNA/DNA substrate observed with DNA/DNA template-primer [50]. The mispair excision
pattern obtained with identical RNA and DNA sequences indicates that the p53 exonuclease
activity for different mismatches is dependent upon the nature of the mispair. The same rel‐
ative order obtained during replication in extracts and in reconstituted reaction, demon‐
strates the reproducibility of the observations, thus indicating that this specificity reflects the
proofreading potential of human replication apparatus.
Among the base substitution mutations, 80% are transitions and 20% are transversions [13].
An interesting observation is that external proofreading activity in the replication apparatus
may preferentially correct some of the misincorporated beses to reduce the rates of transver‐
sions. p53 may affect the mutation spectra of DNA polymerase (e.g. HIV-1 RT) by acting as
an external proofreader [56]. Indeed, HIV-1 RT gains significant benefit from proofreading
with A:G mispair (about 15-fold decrease in A:G mispair extension) as compared with A:C
mipair (about 2.8-fold decrease), since the enzyme has difficulty extending from this particu‐
lar mispair. Furthermore, the low mispair extension capacity implies that DNA polymerase
has a substantially higher probability of dissociation from the transversion mispairs. Disso‐
ciation would prevent mutation fixation, because the mispairs would be subject to removal
by the external p53 proofreading activity. Thus, base substitutions that produce transver‐
sions may be decreased in the presence of p53, indicating that the mutation spectra might be
generated through the actions of RT (DNA polymerase) and cytoplasmic p53 (exonuclease).
The mutational spectra and error rates during DNA synthesis probably depends on the
composition and position of mispair, since each position provides a new set of protein-DNA
contacts. There is the possibility that neighboring nucleotide sequence may influence recog‐
nition of the altered geometry of the mismatch by the enzyme/protein responsible for the




proofreading or/and proofreading efficiency. The fact that p53 binds mismatch in the two
different sequence contexts tested, indicates that the recognition and binding of 3'-terminal‐
ly mismatched DNA substrates by p53 might be independent of the sequence context. Since
formation of exonuclease complexes requires “melting” of the terminal three base pairs at
the primer end, the nature of mismatch at the primer end and the A+T- or G+C-richness of
the primer terminus affect the rate for formation of exonuclease complexes. It has been pro‐
posed that high A-T content of the primer terminus compared with high G-C content in‐
creases excision rates by assisting the strand separation process. Hence, a comprehensive
study of various DNA substrates are needed to determine the effect of local sequence con‐
text on the substrate specificity of the p53 exonuclease and whether p53 could take advant‐
age of A+T richness to prepare duplex DNA for the hydrolysis reaction.
6. Intermolecular pathway of proofreading by p53 exonuclease
Following the incorporation of wrong nucleotide the DNA polymerase stalling and the ki‐
netic delay allows error correction by intramolecular or/and intermolecular pathway [3]. The
intramolecular pathway entails “movement” of the primer end from the polymerase to the
intrinsic exonuclease active site (without dissociating from the DNA). In this way, DNA pol‐
ymerase functions as a “self-correcting” enzyme that removes its own polymerization errors
as it moves along the DNA. The intermolecular proofreading may occur when misinsertion
is followed by polymerase dissociation from the mismatched template-primer, leaving the 3′
terminal mispair accessible to the external exonuclease for binding and error correction. In
both cases, the efficiency of editing misinserted nucleotides by a 3´→ 5´ exonuclease would
be directly dependent on the DNA polymerase capacity to extend from a misincorporated
nucleotide.
Polymerase dissociation at a mispair is an important consideration for proofreading for both
exonuclease-deficient and exonuclease-proficient polymerases, thus allowing error correc‐
tion by a separate 3´→ 5´ exonuclease. The formation of exonuclease complex with the pri‐
mer end of the mismatched DNA participates in error correction during DNA synthesis [42].
A functional interaction between the p53 exonuclease and DNA polymerase activities was
observed. The 3'-terminal mismatched DNA binding and exonuclease activities of p53 are
implicated in the recognition and excision step of mismatch repair. It is conceivable that the
binding of p53 to mismatched DNA and preferential excision of mismatched nucleotides
may be a relevant event in the biological function of the protein in DNA repair. The experi‐
ments in which DNA polymerases, either exonuclease-deficient (e.g. HIV-1 RT) or exonu‐
clease-proficient (e.g. pol γ) were tested for the extension of preformed 3´- terminally
mispaired substrates in the presence of p53 (conditions that mimic a situation of intermolec‐
ular editing), points to a mechanism of mismatch correction prior to polymerization [56,57].
Under DNA replication conditions the un-extended 3'-terminal mismatched DNA produced
following misincorporation, dissociated from the DNA polymerase and was recognized by
p53 (Fig.2). Upon excision of the mispair, p53 exonuclease dissociates and the corrected pri‐
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mer could be transferred to the polymerase and undergo a rebinding process by the DNA
polymerase with a subsequent DNA polymerization.
It is important to note, that DNA polymerase could gain enormous benefit from proofread‐
ing even from a relatively weak exonuclease, if the polymerase has difficulty extending from
a particular mispair [20]. Exonuclease has a dramatic impact on the accuracy of polymerase
by preventing the occurrence of base substitutions during continues DNA replication. All
that is required is discrimination against extension from a mispair within the polymerase ac‐
tive site.
Figure 2. Model for error-correction by p53. The incorporation of wrong nucleotide ( ) into DNA results in DNA poly‐
merase (pol) dissociation from the template-primer, leaving the 3'-terminal mispair accessible to the p53. Upon exci‐
sion of the mispair, the p53 dissociates thus allowing the DNA polymerase to re-associate with the correct 3'-terminus
and resume DNA synthesis.
7. Hallmarks of proofreading and p53 exonuclease activity
Two variables might affect the efficiency of excision from the mispair [1]. First, one hallmark
of proofreading is the “next-nucleotide effect”. Increased proofreading at the expense of




DNA replication is observed at low concentrations of dNTPs, a condition which prevents er‐
ror production during replication in vivo by antimutator DNA polymerases. The enhance‐
ment of the extent of polymerizing activity at the expense of proofreading activity can be
achieved by the presence of high concentrations of dNTPs and dNTP pool imbalances; both
conditions are mutagenic. Increasing the concentration of the next correct nucleotide to be
incorporated following the mispair enhances the probability of mismatch extension, thereby
decreasing proofreading efficiency. Increased polymerizing activity reduces proofreading
even in the presence of a fully functional exonuclease activity. Since a decrease in accuracy
of DNA synthesis with increasing next correct dNTP concentration is a well-established
phenomena of proofreading, the observed dependence of fidelity of DNA synthesis by exo‐
nuclease-deficient DNA polymerase e.g. HIV-1 RT on next nucleotide concentration, implies
that the 3´→ 5´ exonuclease of p53 in cytoplasm might be effective in eliminating polymer‐
ase-catalyzed base-substitution errors [56]. This effect supports a coordinated action of the
p53-exonuclease in cytoplasm with HIV-1 RT during DNA synthesis.
Second, the polymerase/exonuclease ratio serves as an important enzymatic “marker’ of pol‐
ymerase fidelity [1]. Exonucleolytic proofreading is a major determinant of replication fideli‐
ty. The balance between the DNA polymerizing and 3´→ 5´ exonuclease reactions usually
affects the overall accuracy of DNA synthesis to ensure optimal DNA replication efficiency
and to prevent excessive DNA degradation of correctly synthesized DNA. The high ratio of
exonuclease to polymerase at the constant dNTP concentrations may increase the fidelity of
DNA synthesis.
Cellular responses to DNA damage include repair processes that act coordinately prior to,
during and after DNA replication, to maintain genomic stability. The accuracy of DNA syn‐
thesis might respond to alterations in composition of replication complex. p53 function may
be regulated by controlling where the protein is in the cell. Various stress conditions may
trigger distinct signaling pathways in controlling p53 nucleo–cytoplasmic-mitochondrial
translocation, thus contributing to heterogeneity of p53-dependent responses. The identifi‐
cation of the p53 protein in cytoplasm or in mitochondria that may enhance the fidelity of
DNA polymerase suggests that the accuracy of DNA synthesis by the enzyme may respond
to alterations in composition of replication complex. Most probably, p53 in nucleus or cyto‐
plasm or mitochondria might have a transient interaction with replication complex. There‐
fore, the DNA synthesis in each compartment may be dynamic process with p53 component
binding and dissociating the DNA polymerization complex during dsDNA synthesis, thus
affecting the polymerase/exonuclease (p53) ratio. The change in the ratio of DNA polymer‐
ase vs exonuclease (p53) could be achieved through a reduction in polymerization efficiency
of DNA polymerase due to mutations, or from over-expression of p53, or through p53 gene
induction (increase in p53 concentration) or p53 targeting (increase in local nuclear or cyto‐
plasmic or mitochondrial concentration). p53 is able to excise 3'-terminal nucleotides during
the ongoing DNA synthesis i.e. coupled with DNA polymerization and following direct
binding to template-primer i.e. independent of DNA polymerase, thus increasing the poten‐
cy of involvement of the protein during the DNA replication by acting as an external proof‐
reader in each cellular compartment. Consequently, the presence of p53 in nucleus/
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cytoplasm/mitochondria, by carrying these properties, may be relevant to the accuracy of
DNA synthesis by various DNA polymerases.
8. Excision of nucleoside analogs from DNA by p53 protein
Many nucleoside analogs (NAs), potent anti-cancer and antiviral drug compounds, include
a variety of purine and pyrimidine nucleoside derivatives which may compete with physio‐
logical nucleosides. Nucleoside analogs, clinically active in cancer chemotherapy (e.g. Ara-C,
in the treatment of hematological malignancies, or gemcitabine-dFdC, against a variety of
solid tumors) and in treatment of virus infections (e.g. 3´-azido-2,3,-deoxythymidine-AZT,
2,3-dideoxycitidine-ddC, inhibitors of HIV-1 RT), are incorporated into DNA and cause cell
death or inhibition of viral replication [82,83]. These drugs are intracellularly converted to
the active analog trophosphates, which are then incorporated into replicating DNA. The in‐
corporated NA, structurally mimicing a mismatched nucleotide at the 3'-terminus, blocks
further extension of the nascent strand (chain termination) and causes stalling of replication
forks with higher probability to the dissociation of the enzyme from template-primer. The
high toxicity of dideoxynucleotide compounds may be caused by high rates of incorporation
of the NA into mtDNA and the persistence of these analogs in mtDNA due to inefficient ex‐
cision. Analysis of the processes involved in the removal of NAs and repair of stalled forks
is important to better understand the mechanisms that spare toxicity to these drugs.
Proofreading exonuclease activity is capable of removing wrong nucleotides from DNA,
providing a mechanism that potentially causes drug resistance. In general, the amount of
NAs presented at the DNA termini depends on the efficiency of the incorporation of the
compounds by DNA polymerases and on the rate of excision by 3´→5´ exonucleases [83].
The excision of the incorporated NA from the 3’-end of DNA by exonucleases may decrease
their potential for chain termination and may be viewed as a potential cellular mechanism of
resistance to anti-viral drugs or anti-cancer NAs. The role of p53 exonuclease in maintaining
genomic stability in mammalian cells is particularly relevant with respect to the develop‐
ment of anticancer and antiviral therapies.
Many anticancer agents induce cellular cytotoxicity by causing DNA damage. Cells devel‐
oped several repair mechanisms to facilitate the excision of incorporated NAs. The cyto‐
toxic  activity  of  gemcitabine  (2'2'-difluorodeoxycitidine,  dFdC)  was  strongly  correlated
with the amount of dFdCMP incorporated into cellular DNA. Interestingly, dFdCTP incor‐
poration by human DNA polymerase α results in “masked termination” of DNA synthe‐
sis, where following a single dFdCTP incorporation into DNA, the primer is extended by
only one additional dNTP before polymerization is inhibited [84]. The p53 protein recog‐
nizes dFdCMP-DNA in whole cells, as evidenced by the fact that p53 protein rapidly ac‐
cumulated in the nuclei of the gemcitabine treated ML-1 cells [85]. Although, the excision
of the dFdCMP at the penultimate position from the 3’-end of the DNA was slower than
the excision of matched or mismatched nucleotides in whole cells with wtp53 (ML-1) and
not detectable in CEM cells harboring mutant p53. ML-1 cells were more sensitive to the




cytotoxic effect of the drugs compared to the p53-null or mutant cells. Transfection of p53-
null  cells  with  wild-type  p53  expression  vector  enhanced  the  sensitivity  of  the  cells  to
gemcitabine. Taken together, these authors concluded that recognition of the incorporated
NAs in DNA by wild-type p53 did not confer resistance to gemcitabine, but may have fa‐
cilitated the apoptotic cell death process. It was reported that treatment with gemcitabine
resulted in an increased production of DNA-dependent protein kinase (DNA-PK) and p53
complex  in  nucleus,  that  interacts  with  the  gemcitabine-containing  DNA [86].  DNA-PK
and p53 sensor complex may serve as a mechanism to activate the pro-apoptosis function
of p53. Apparently, the prolonged existence of the NA-stalled DNA end induced the kin‐
ase activity, which subsequently phosphorylated p53 and activated the downstream path‐
ways leading to apoptosis.
Remarkably, p53 present in complex with DNA-PK exhibited 3′→5′ exonuclease activity
with mismatched DNA, however the active p53 was unable of excising efficiently the incor‐
porated drug from NA-DNA construct containing gemcitabine at the penultimate site and a
matched pair at the 3’-end [86]. It should be noted, that the specific effects of gemcitabine
exposure appeared to vary depending on the duration of treatment and upon the cell line.
The drug-induced apoptosis were further compared in two lines derived from the MCF-7
cells: MN-1 cells with wild-type p53 and MDD2 cells containing mutant p53 [87]. The MDD2
cells were significantly more resistant to gemcitabine induced cytotoxicity than the MN-1
cells. Unexpectedly, MDD2 cells accumulated more gemcitabine than MN-1 cells, with high‐
er incorporation into nucleic acids. The activation of gemcitabine to its phosphorylated form
was similar in both cell lines and it was suggested that the absence of 3´→5´ exonuclease ac‐
tivity in the mutant p53 cell line accounted for the enhanced incorporation into nucleic
acids. The presence of a dysfunctional p53, presumably, allows the cells that accumulate
DNA damage to continue proliferating. It should be pointed out, that wild-type p53 in ML-1
cells removed the purine nucleoside analog fludarabine (F-ara-A) more efficiently than gem‐
citabine [85]. Further studies are needed to assess the role of p53 in cellular response to vari‐
ous anti-cancer purine and pyrimidine NA-induced DNA damage.
HIV-1 RT readily utilizes many NAs and the incorporation of nucleoside RT inhibitors
(NRTIs) into the 3’-end of viral DNA leads to chain termination of viral DNA synthesis in
cytoplasm [88]. The ability of p53 exonuclease activity to excise NA from DNA was studied.
A decrease in incorporation of the NA (e.g. ddTTP or ddATP) into DNA by HIV-1 RT was
shown during both RNA-dependent and DNA-dependent DNA polymerization reactions in
the presence of either purified recombinant p53 or endogenous protein provided by cyto‐
plasmic fraction of LCC2 cells [89]. Furthermore, p53 in the cytoplasm was able to excise the
incorporated 3’-terminal NAs, although less efficiently than the matched or mismatched nu‐
cleotides; longer incubation times were required for excision of the terminally incorporated
analogs. In control experiments, no reduction in incorporation of either ddTTP or ddATP
was observed in the presence of cytoplasmic fraction of H1299 (p53-null) cells. These data
suggest that p53 in cytoplasm may act as an external proofreader for NA incorporation and
confer cellular resistance mechanism to the anti-viral compounds.
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Acquired mitochondrial toxicity occurs as a consequence of incorporation of anti-cancer or
anti-viral NA into mtDNA and/or inhibition of mtDNA replication [90,91]. NRTIs, in addi‐
tion to the target viral polymerase in cytoplasm (antiviral activity), can be incorporated into
a mtDNA by pol γ, leading to termination of mtDNA synthesis and mitochondrial dysfunc‐
tion (host toxicity). Mitochondrial toxicity may be caused by termination of the growing nas‐
cent DNA strand after incorporation of the NRTIs into mtDNA or by inhibition of pol γ
exonucleolytic proofreading [90,91]. DNA synthesis/repair proceeding in nucleus-free mito‐
chondria, relies upon a preassembled DNA replication machinery of pol γ and multiple pro‐
teins to maintain mtDNA integrity. p53 in mitochondria may functionally interact with pol
γ, thus providing a proofreading function during mtDNA replication for excision of NAs
[92]. Indeed, increased excision of the incorporated NAs from DNA was detected with
H1299mit in the presence of recombinant or endogenous wild-type p53 but not exonuclease-
deficient mutant p53-R175H: Mitochondrion-localized elevation of p53 following the IR-
stress stimuli correlates with the low incorporation of NA. The fact that p53 localizes to the
mitochondria and interacts with mtDNA and pol γ, taken together with observations that
the presence of p53 (provided by recombinant or endogenous p53) reduces the amount of
incorporation of NA in H1299mit, suggests that p53 may potentially participate in NA exci‐
sion. p53 in mitochondria probably have a transient interaction with replication complex;
the DNA synthesis may be dynamic process with p53 component binding and dissociating
the polymerization complex during DNA synthesis, thus affecting the polymerase (pol γ)/
exonuclease(p53) ratio. Consequently, the decrease in the ratio of pol γ/p53 due to the in‐
crease in local p53 concentration in mitochondria, may enhance the proofreading efficiency
and excision of NA by external p53. Knowledge of the mechanism of inhibition of pol γ may
be utilized to obtain selectivity for HIV-1 RT over pol γ. The removal of the incorporated
NRTI by p53 exonuclease, indicates that the presence of the cellular component-p53 in mito‐
chondria may be important in defining the cytotoxicity of NRTIs toward mitochondrial rep‐
lication, thus affecting risk-benefit approach (NRTI toxicity versus viral inhibition).
Although dFdC is not a chain terminator, the extension of a dFdCMP-terminated primer
is 25-fold slower than the extension of a canonical  DNA primer in mitochondria.  More‐
over, the primer 3′-dFdCMP was excised with a 50-fold slower rate than the matched 3′-
dCMP. Given that  mtDNA repair  is  limited and inefficient  [93],  persistence of  dFdCMP
within mtDNA is predicted to be likely. The toxicological profile of gemcitabine resembles
that of many other anti-viral nucleoside analogs and frequently mimics the symptoms of
heritable mitochondrial defects. The mitochondria may be able to remove chain-terminat‐
ing  nucleoside  analogs  and  resume normal  mtDNA  replication,  but  nucleoside  analogs
that do not chain terminate, and therefore can become part of the mitochondrial genome,
may exert long term toxicity [85]. pol γ was able to extend a DNA primer containing 3′-
dFdCMP  although  with  decreased  nucleotide  incorporation  efficiency  at  the  first  two
downstream positions. p53 is able to remove the incorporated anti-cancer drug arabinosyl‐
cytosine (Ara-C) (pyrimidine analog) from DNA incorporated by pol γ in mitochondrial
fraction of  p53-null  cells  [92].  The binding and removal  of  chemically active anti-cancer
and anti-viral NAs from DNA by p53 may lead to either drug resistance or activation of
p53 pro-apoptotic functions (Fig.3).




Figure 3. The potential functions of p53 in response to nucleoside analog-induced DNA damage. The p53 protein,
following the recognition and preferential binding to the drug-containing DNA could display two different functions:
the removal of the incorporated NA from DNA, thus conferring the resistance to the drugs, or may serve as a mecha‐
nism to activate the pro-apoptosis function of p53 and trigger the cell death program.
p53 is a multifunctional protein with positive and negative effects. In general, drug resist‐
ance that occurs in cancer chemotherapy and antiviral therapy is a negative event that will
decrease the efficacy of the treatment. The behavior of p53 exonuclease probably depends
on the sub-cellular localization of the p53, local concentration, nature of NA (purine, pyrimi‐
dine), position of the NA (3’-terminal NA, analog residue at the penultimate position and
nature of the subsequent correct nucleotide) and on the local DNA sequence composition.
The recognition and removal of NA from drug-containing DNAs by p53 exonuclease activi‐
ty in various compartments of the cell may play a role in decreasing drug activity, leading to
various biological outcomes: 1)the excision of the incorporated NA from DNA in nucleus
may confer resistance to the drugs (negative effect) [85]; 2)the removal of the NA by p53
from DNA incorporated by HIV-1 RT in cytoplasm may confer resistance to the drugs by
non-viral mechanism (negative effect) [89] and 3)the excision of NAs from mitochondrial
DNA may decrease the potential for chain termination and host toxicity (positive effect)
[92]. Apparently, the presence of p53 in mitochondria may be important, since the excision
of the mispair and NA by p53 is favorite event for mitochondrial function.
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9. Conclusions and perspectives
Nature has devised multiple strategies to safeguard the genetic information and developed
intricate repair mechanisms and pathways to reverse an array of different DNA lesions, in‐
cluding mismatches. An accessory proofreading exonuclease would be critical for the re‐
moval of the mispairs and therefore, for the maintenance of genomic integrity. The high
incidence of mutations may be due to misinsertion and proofreading deficiency of DNA pol‐
ymerases [65]. Mammalian cells have evolved several repair mechanisms for the mainte‐
nance of genomic integrity to prevent the fixation of genetic damage induced by
endogenous and exogenous mutagens [3]. Cells may have several 3‘→5’ exonucleases to pre‐
serve genomic integrity during DNA synthesis. Under conditions where the activity of one
exonuclease is inactivated, the function of another exonuclease might be important for cor‐
recting errors produced during DNA replication. p53 was shown to be an example of acces‐
sory protein that may enhance the fidelity of DNA synthesis by exonuclease-deficient DNA
polymerase, e.g. HIV-1 RT [56] and exonuclease-proficient DNA polymerase, e.g. pol γ [57]
in various compartments of the cell: nucleus, cytoplasm and mitochondria. The preferential
excision of mismatched nucleotides from the replicating DNA strand by p53, implies that
this cellular error-correction pathway may compensate for a lack of effective proofreading of
DNA polymerase induced replication errors. In addition, the proofreading activity of p53
may limit the tranversion mutations, indicating that p53 may affect the mutation spectra of
DNA polymerase by acting as an external proofreader. The mutagenic capacity of a low fi‐
delity DNA polymerase will be decreased through increase in exonuclease concentration or
exonuclease targeting (increase in local p53 concentration).
p53 plays a pivotal role in the regulation of cell fate determination in response to a variety of
cellular stresses. p53 may exert the functional heterogeneity in its non-induced and in its ac‐
tivated state. Furthermore, p53 is able to elicit a spectrum of different biological effective
pathways in nucleus, cytoplasm and mitochondria. The increase of p53 protein levels will
increases the amount of p53 with a 3´→5´ exonuclease activity. Hence, it is of interest to elu‐
cidate 3´→ 5´ exonuclease activity nucleus, cytoplasm and mitochondria of the cells with ac‐
tivated p53 induced by drug treatments (in the absence of DNA damage) or following UV
irradiation (in the presence of DNA damage).
The role of p53 is particularly relevant with respect to the development of anticancer and
antiviral therapies. The potency of NAs is dependent upon their incorporation at the 3’ ends
of replicating DNA. However, clinical drug resistance limits the efficacy of these com‐
pounds. Cells have evolved several repair mechanisms to facilitate the excision of misincor‐
porated nucleotides or nucleoside analogs. Uncovering the mechanisms, which are
responsible for DNA repair of NA-induced DNA damage will have therapeutic value. The
stress induced activation of p53 that occurs during cancer chemotherapy has negative and
positive effects. The p53 protein is able to remove incorporated NA. Therapeutic strategies
based on p53 are particularly interesting because they exploit the cancer cell’s intrinsic ge‐
nome instability and predisposition to cell death-apoptosis. p53 may remove incorporated
therapeutic NAs from DNA or trigger apoptosis. The knowledge regarding functions of p53




in genome integrity and cancer evolution may facilitate drug screening and better design of
therapeutic approaches.
10. Future directions
The functional interaction between p53 and DNA polymerase may have important conse‐
quences for the maintenance of genomic integrity and pose significant challenges to the de‐
velopment of p53-targeting cancer therapies. Mutant p53 can be classified as a loss-of-
function or gain-of-function protein depending on the type of mutation [27,28].
Characterization of exonuclease-deficient H115N mutant p53 revealed that although exonu‐
clease-mutant H115N p53 can induce cell cycle arrest more efficiently than wild-type p53, its
ability to produce apoptosis in DNA damaged cells is markedly impaired [60]. Does exonu‐
clease-mutant p53 promote mismatch genetic instabilities? What is the ultimate phenotypic
result of this genomic instability? Is it truly contributing to the increased proliferation, seen
in tumors of mutp53 mice, and can these results be extended to human tumors? In order to
answer these questions, more studies must be conducted on the biology of various mutant
p53's and their interaction with the factors involved in DNA repair and apoptosis. Charac‐
terizing the instability phenotype of cells after perturbing these interactions will lead to a
better understanding of the main causes of mutant p53-mediated genomic instabilities,
which might also be point mutant-specific. p53 have a dual role in response to therapy, as
exonuclease that by excision of incorporated anti-cancer drugs may confer resistance to
drugs or as mediator of cell death induced by chemotherapy [85]. These features could serve
as a template for the development of p53-targeting cancer therapies.
A major focus in the future would be to characterize the cellular and biological functions of
p53 in mitochondria in response to various stresses. There are many missing points about
the biological roles of p53 in mitochondria that still remain to be identified. How p53 can be
imported into mitochondria? Whether p53 determines the percent of mutated mtDNA (het‐
eroplasmy in a cell)? Uncovering the mechanisms by which pol γ-mediated mtDNA muta‐
tions and depletion are manifested in tissues in the absence and presence of p53 is the next
step in understanding causes for mtDNA –related diseases. Understanding how p53 can be
imported into mitochondria, will be important and could contribute towards the design of
new therapies for cancer and other diseases.
The control of the viral mutation rate could be a viable anti-retroviral strategy. Still more
work needs to be done in order to understand the molecular mechanisms involved in con‐
trolling fidelity not only at a molecular level (i.e., intrinsic RT fidelity), but also related to the
cytoplasmic p53 protein that can modulate the viral mutation rate and affect the incorpora‐
tion of NRTIs into viral DNA. New understandings of the sub-cellular localization of p53, its
role in the fidelity of proviral DNA synthesis in cytoplasm and drug resistance, therefore,
may have broad implications for cellular and molecular biology as well as medicine. It may
form the basis for new strategies in targeted antiviral therapy that focus on the sub-cellular
context of p53 in cells.
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Depletion and mutation of mitochondrial DNA during chronic NRTI therapy may lead to
cellular respiratory dysfunction and release of reactive oxidative species, resulting in cellu‐
lar damage [91]. Future NRTIs should provide higher specificity for HIV-RT and lower in‐
corporation by pol γ to minimize mitochondrial toxicity. Whether the effective targeting of
p53 in mitochondria may result in decrease of mitochondrial toxicity in response to conven‐
tional anti-viral therapies? Further studies are needed to elucidate if p53, by error-correction
functions in mitochondria, can decrease mitochondrial toxicity.
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